AM-103 (drug)

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-(2-methylpropyl)phenyl]methyl]propanoic acid | image = | width = 200 | CAS_number = 123456-78-9 | PubChem = 123456 | ChemSpiderID = 123456 | UNII = 123456789A | KEGG = D12345 | ChEMBL = 1234567 | ATC_prefix = | ATC_suffix = | C = 13 | H = 18 | O = 2 | molecular_weight = 206.28 g/mol }}

AM-103 is a synthetic compound that has been investigated for its potential use as a pharmaceutical drug. It is primarily studied for its effects on the central nervous system, particularly in the modulation of neurotransmitter systems.

Pharmacology

AM-103 is believed to act as a modulator of the serotonin and dopamine systems, which are critical pathways in the brain involved in mood regulation, cognition, and reward. The exact mechanism of action of AM-103 is not fully understood, but it is hypothesized to influence the reuptake or release of these neurotransmitters, thereby altering synaptic transmission.

Clinical Trials

As of the latest updates, AM-103 has undergone several phases of clinical trials. In early-phase trials, it demonstrated a favorable safety profile with mild to moderate side effects, which were generally well-tolerated by participants. The primary focus of these trials was to assess the efficacy of AM-103 in treating conditions such as major depressive disorder and anxiety disorders.

Potential Applications

The potential applications of AM-103 extend beyond mood disorders. Preliminary studies suggest that it may have utility in treating neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, due to its neuroprotective properties. However, more research is needed to confirm these effects and to understand the long-term implications of its use.

Chemical Properties

AM-103 is a small molecule with a molecular weight of 206.28 g/mol. It is characterized by its lipophilic nature, which allows it to cross the blood-brain barrier effectively. The compound is typically synthesized through a series of chemical reactions starting from commercially available precursors.

Regulatory Status

As of now, AM-103 has not been approved by major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for clinical use. It remains an investigational drug, and its development is subject to ongoing research and clinical evaluation.

Also see

• Serotonin reuptake inhibitor
• Dopamine receptor antagonist
• Neurotransmitter
• Clinical trial

Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology